What is Nintx?
Nintx specializes in leveraging the potential of plant-based natural products to modulate human biological targets and the gut microbiome. The company's core focus is on developing multi-target therapies for various multifactorial diseases. By utilizing advanced technologies and fostering strategic partnerships with research institutes and private companies, Nintx aims to enhance its research and development capabilities and bring novel pharmaceuticals and nutraceuticals to market. The company's approach is rooted in understanding the intricate connections between plants, microorganisms, and human health.
How much funding has Nintx raised?
Nintx has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2024): $10M with participation from Ecoa Capital, Grupo Adeste, Prefeitura Municipal de Pitanga, Laboratório Tiaraju, and MOV Investimentos
Key Investors in Nintx
Ecoa Capital
Ecoa Capital is an investment firm focused on generating social, environmental, and economic value through strategic investments in companies and managers aligned with contemporary challenges. They invest in businesses that have the potential for transformation, enhancing their operations or product offerings to meet modern consumer needs.
MOV Investimentos
MOV Investimentos is a Brazilian impact investment management firm focused on supporting entrepreneurs and investing in innovative companies to reduce social inequalities and reverse environmental degradation. Their portfolio includes investments that generate substantial socio-environmental impacts.
Laboratório Tiaraju
Grupo Tiaraju is dedicated to providing high-quality natural products aimed at promoting health and well-being, with a focus on innovative and pioneering dietary supplements and medications for intestinal health, immunity, and more.
What's next for Nintx?
With this recent strategic investment, Nintx is poised for a significant scaling phase. The enterprise-level funding suggests a transition from early-stage development to broader market penetration and pipeline expansion. Future endeavors will likely involve further clinical trials, regulatory approvals, and the establishment of robust manufacturing and distribution channels. The company's focus on microbiome-targeted therapies aligns with a growing global interest in personalized medicine and natural product-based treatments, positioning Nintx for substantial growth and impact in the pharmaceutical and nutraceutical sectors.
See full Nintx company page
